UAB

Nuclear Transfer Of Mitochondrial DNA In Colon And Rectal Cancer

ArticlePress release
Digestive Health
Current Medical News
+2
Contributed byKrish Tangella MD, MBAApr 21, 2017

Patients with colon and rectal cancer have somatic insertions of mitochondrial DNA into the nuclear genomes of the cancer cells, University of Alabama at Birmingham researchers report in the journal Genome Medicine.

This study provides the novel role for mitochondria inducing genomic instability in the nucleus of cancer cells, the UAB researchers say.

Overall, a study of the genome sequences of 57 colorectal cancers showed, on average, 4.42-fold more somatic nuclear mitochondrial DNA as compared to matched healthy blood controls. This suggests that migration of mitochondrial DNA into the nuclear genome plays an important role in development of cancer, say corresponding authors Hemant K. Tiwari, Ph.D., and Keshav K. Singh, Ph.D. Tiwari is professor of biostatistics in the UAB School of Public Health, and Singh is professor of genetics in the UAB School of Medicine.

Numerous mitochondrial organelles reside in nearly all higher eukaryotic cells, and they function as the powerhouses of the cells to create ATP, the cell's major energy source. Human mitochondria have just 37 genes. The mitochondria are located in the cytosol of the cells, outside of the cell nucleus; the cell's DNA genome is located inside the nuclear membrane.

Over eons, pieces of mitochondrial DNA have naturally inserted into eukaryotic genomes; at birth, for example, humans have between 755 and 1,155 germline mitochondrial DNA inserts that have been passed on through generations. These germline, inherited mitochondrial DNA insertions are seen over a wide range of organisms, including humans, plants, yeast, malaria parasites and nematodes.

Besides DNA, entire mitochondria, mitochondrial proteins and mitochondrial RNA can also be found in the nucleus; but their roles in human health and disease remain relatively unexplored. The increased mitochondrial DNA in the genomes of the cancer cells observed by the UAB team suggests somatic insertion of mitochondrial DNA occurred as the cancer developed.

The median nuclear mitochondrial DNA fold-change in colorectal tumors of women was higher than the median for men. There appeared to be a correlation of increased fold-change with poorer patient survival, but the researchers say further analysis of a larger sample size is needed to make a definite conclusion.

The somatic mitochondrial DNA inserts appeared to correlate with gene-rich segments of the genome, and the researchers mapped hotspots on the mitochondrial genome for migration into the nuclear genome.

Since the gene product of YME1 is a potent suppressor of mitochondrial DNA migration into the genome of the yeast Saccharomyces cerevisiae, Tiwari and Singh investigated the human homologue of the YME1 gene, called YME1L1. Both gene products have conserved roles in mitochondrial assembly (mitochondria are made up of 2,000 proteins encoded by the nuclear genome and 13 encoded by the mitochondrial genome), mitochondrial integrity and DNA metabolism. However, a role for the human YME1L1 in suppressing migration of mitochondrial DNA into the nucleus was unknown.

As indirect evidence, the UAB researchers found that 16 percent of the 57 colorectal cancer sequences examined had mutations in the human gene YME1L1. An expanded analysis of colorectal cancer sequences in The Cancer Genome Atlas database showed a high incidence of YME1L1 mutations. The researchers also found high mutation rates of YME1L1 in other cancers.

The UAB team next showed that knocking out YME1L1 in a human cell line strikingly increased the amount of mitochondrial DNA in the nuclear fraction of YME1L1 knockout cells. These results identified YME1L1 as the first reported suppressor gene for nuclear migration of mitochondrial DNA in humans, and they suggested that inactivation of YME1L1 leads to increased migration of mitochondrial DNA into the nucleus.

This was tested in yeast. A marker that can only be transcribed in the nucleus was inserted into yeast mitochondrial DNA. When the yeast YME1 was mutated, the marker was 20-fold elevated compared to yeast with non-mutated YME1. When human YME1L1 was introduced into yeast with the mutated YME1, the human gene product partially rescued the YME1 mutation, preventing migration of mitochondrial DNA into the nucleus. Thus, human YME1L1 appears to suppress migration of mitochondrial DNA into the nucleus.

Tiwari and Singh have dubbed a new term -- numtogenesis (pronounced "noo-mitto-genesis") -- for this phenomenon of mitochondrial occurrence in the nucleus.

In a companion paper in Analytical Biochemistry, the Singh laboratory and the Bernd Friebe laboratory at the Department of Plant Pathology, Kansas State University, describe a molecular tool to rapidly detect and analyze insertion of mitochondrial DNA into the genomes of cells.

Up to now, analysis of mitochondrial DNA inserted into the nuclear genome depended on deep genome sequencing combined with comprehensive computational analysis of the entire genome, a time-consuming, cumbersome and cost-prohibitive approach. The researchers, led by corresponding author Singh and first author Dal-Hoe Koo, research assistant professor at Kansas State, developed a single-molecule mitochondrial Fiber-FISH technique, using fluorescence in situ hybridization. This permits high-resolution mapping of genes and chromosomal regions on single fibers of DNA, and it targets the physical location of mitochondrial DNA probes down to a resolution of 1,000 base pairs.

"This novel technique," they said, "should help distinguish and monitor cancer stages and progression, aid in elucidation of basic mechanisms underlying tumorigenesis, and facilitate analyses of processes related to early detection of cancer, screening and/or cancer risk assessment."


Materials provided by University of Alabama at BirminghamNote: Content may be edited for style and length.

Disclaimer: DoveMed is not responsible for the accuracy of the adapted version of news releases posted to DoveMed by contributing universities and institutions.

Primary Resource:

  1. Srinivasainagendra, V., Sandel, M. W., Singh, B., Sundaresan, A., Mooga, V. P., Bajpai, P., ... & Singh, K. K. (2017). Migration of mitochondrial DNA in the nuclear genome of colorectal adenocarcinoma. Genome Medicine9(1), 31. DOI: 10.1186/s13073-017-0420-6
  2. Koo, D. H., Singh, B., Jiang, J., Friebe, B., Gill, B. S., Chastain, P. D., ... & Singh, K. K. (2017). Single-molecule mtDNA fiber FISH for analyzing numtogenesis. Analytical Biochemistry. DOI: 10.1016/j.ab.2017.03.015

Was this article helpful

On the Article

Krish Tangella MD, MBA picture
Approved by

Krish Tangella MD, MBA

Pathology, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!